INTREPAD stands for Investigation of Naproxen TReatment Effects in Pre-symptomatic Alzheimer’s Disease.
This trial was intented to determine if a low dose of anti-inflammatory drug would change the trajectory of the presymptomatic progression of AD. This presymptomatic progression was tracked by a multimodal composite score, the Alzheimer Progression Score.
See the recently published results paper, here.
- Duration: Two-year
- Design: Randomized, placebo-controlled, double-masked
- Study drug: naproxen sodium 220 mg b.i.d, versus placebo (1:1)
- Population: PREVENT-AD participants, enrolled: n=195, included in analysis n=160